{"id":"W2207970920","doi":"10.1111/dom.12624","title":"Patient‐reported outcome results in patients with type 2 diabetes treated with once‐weekly dulaglutide: data from the <scp>AWARD</scp> phase <scp>III</scp> clinical trial programme","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Exenatide; Medicine; Checklist; Type 2 diabetes; Diabetes mellitus; Internal medicine; Quality of life (healthcare); Physical therapy; Psychology; Endocrinology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004842598,0.0003841112,0.0013819,0.0005939677,0.0002216585,0.0006678139,0.0003602533,0.0006329302,0.001029868],"category_scores_gemma":[0.004456945,0.0001535956,0.001916535,0.0009898097,0.0001958225,0.0005674679,0.0003301826,0.0009246481,0.0001748814],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000308561,"about_ca_system_score_gemma":0.0002950342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007503941,"about_ca_topic_score_gemma":0.001155458,"domain_scores_codex":[0.9979604,0.001049377,0.0003299662,0.0001889275,0.0003543912,0.0001168269],"domain_scores_gemma":[0.9918808,0.003035191,0.003353238,0.0003374229,0.0006739593,0.000719349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1358357,0.003267742,0.8028287,0.001260137,0.007236043,0.0002473525,0.0003273434,0.001618113,0.002505965,0.00005486732,0.001336981,0.04348105],"study_design_scores_gemma":[0.006476151,0.02252109,0.9666027,0.0000514073,0.001865141,0.0002112744,0.00009762911,0.0006718707,0.0005674172,0.00003705308,0.0008524875,0.0000458161],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931203,0.002737069,0.0002046413,0.000074258,0.00002207109,0.0001612261,0.00268881,0.00001351742,0.0009782661],"genre_scores_gemma":[0.9947609,0.0005473911,0.0002468287,0.00009826558,0.00004153559,0.0002369293,0.003753767,0.000005267214,0.0003091493],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004842598,"threshold_uncertainty_score":0.02561039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08649019103364348,"score_gpt":0.3185098796536899,"score_spread":0.2320196886200465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}